Skip to main content
Fig. 8 | BMC Cancer

Fig. 8

From: Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomised controlled trials

Fig. 8

Forest plots of the pooled RRs for the ORR, disease control, and grade 3 or higher hematological (including neutropenia, and anemia) and non-hematological (including pneumonia, diarrhea, and fatigue) adverse events of the patients with MM in the MAbs targeting PD-1/PD-L1 group versus control group. The RRs for the ORR and disease control > 1 favour the MAb group. The RRs for the incidence of adverse events < 1 favour the MAb group. The size of the blocks or diamonds represents the weight of the fixed effects model in the meta-analysis

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us